EVOK - What am I missing?

anonymous

Guest
Anyone else have thoughts on this one? Too small for institutional money to dive into right now, but that seems to be the only reason this thing isn't closer to $8, the setup looks pretty perfect. Phase 2 data in gastroparesis is solid, and Phase 3 design is similar. We should see data by June/July and they have cash runway through October. Also, I've never heard a company so open about selling the company after the data readout. Am I missing something?